Clearfield Inc. (NASDAQ:CLFD) which deploys fiber networks in commercial and multi-residence buildings, reported a profit of $1.2 million on revenue of $13.2 million for the January-to-March period, the second quarter of its fiscal year. Both numbers were in line with expectations.
Clearfield Inc. (NASDAQ:CLFD) shares after opening at $15.80 moved to $17.29 on last trade day and at the end of the day closed at $16.64. Company price to sales ratio in past twelve months was calculated as 3.65 and price to cash ratio as 10.30. Clearfield Inc. (NASDAQ:CLFD) showed a negative weekly performance of -18.27%.
On April 11, 2014, Synthesis Energy Systems, Inc. (NASDAQ:SYMX) entered into a letter agreement with Lorenzo Lamadrid, the Chairman of the Company’s Board of Directors (the “Board”), amending the terms of his consulting agreement with the Company dated May 30, 2006, as amended on August 15, 2010. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) shares fell -0.56% in last trading session and ended the day on $1.77. SYMX return on equity ratio is recorded as -21.30% and its return on assets is -18.70%. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) yearly performance is 62.39%.
Zhone Technologies, Inc. (NASDAQ:ZHNE), a global leader in FTTx network access solutions, on 22 April reported its financial results for the quarter ended March 31, 2014. Zhone Technologies Inc. (NASDAQ:ZHNE) shares moved down -9.97% in last trading session and was closed at $2.89, while trading in range of $2.88 – $3.21. Zhone Technologies Inc. (NASDAQ:ZHNE) year to date (YTD) performance is -45.88%.
CEL-SCI Corporation (NYSEMKT:CVM) a late-stage oncology company announced that the Company is a Gold Sponsor of the Congress on Head and Neck Oncology (ECHNO 2014), which will be held in Liverpool, England from April 24th through 26th, 2014. CEL-SCI will sponsor a symposium regarding its investigational immunotherapy candidate Multikine®* (Leukocyte Interleukin, Injection) and its ongoing Phase III head and neck cancer trial with Multikine. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is -9.45%. On last trading day company shares ended up $1.15. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is -16.38%. Analysts mean target price for the company is $7.00.